About the API
Mometasone furoate is a synthetic corticosteroid for multiple uses according to route of administration: inhalation, topical or intranasal. As an inhalant (an ICS inhaled corticosteroid), it is prescribed for the maintenance treatment of asthma as prophylactic (preventive) therapy.
The inhalation powder can be used for ages four and older; the inhalation aerosol can be used for ages 12 and older. As a topical cream, lotion, or ointment it is prescribed for the relief of the inflammatory and pruritic (itchy) manifestations of corticosteroid-responsive dermatoses (skin conditions), for ages two and older.
As a nasal spray, it is prescribed for treatment of the symptoms seasonal (outdoor) and year-round (indoor) allergic rhinitis in adults and children 2 years and older, the prophylactic treatment of seasonal allergic rhinitis for ages 12 and older, and the treatment of nasal polyps for ages 18 and older.
Mometasone furoate was approved by the FDA for topical use in 1987 for intranasal use in 1997 and for inhalation, as a powder, in 2005. The aerosol was approved in 2014. It is produced through multi-step chemical synthesis.